EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antibody responses to Japanese encephalitis virus and dengue virus serotype 2 in children from an orthoflavivirus endemic region after IMOJEV vaccination

Fatima Ericka S Vista iD, Leslie Michelle M Dalmacio, Pauline R Solis, Cecilia Nelia C Maramba-Lazarte, Diane M Lang, Alan L Rothman, Sheriah Laine M de Paz-Silava

PLOS Neglected Tropical Diseases · 2025

DOI: 10.1371/journal.pntd.0013550 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Fatima Ericka S Vista und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, College of Medicine, University of the Philippines Manila, Manila, Philippines. Hauptthemen laut MEDLINE: Antibodies, Viral, Encephalitis Virus, Japanese, Dengue Virus, Japanese Encephalitis Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Fulbright fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Japanese encephalitis virus (JEV) is a mosquito-borne pathogen that causes severe neurologic disease. Its endemicity in Asia has prompted its inclusion in nationwide immunization programs. However, the Philippines, which is also endemic for related viruses like dengue (DENV), has not yet adopted this practice. Vaccine hesitancy is a major challenge, exacerbated by concerns over cross-reactive antibodies that may enhance viral infection. This study aimed to determine whether IMOJEV vaccination would induce cross-neutralizing or enhancing antibodies against DENV. Methodology/Principal findings Pre- and one-month post-vaccination samples from IMOJEV-vaccinated Filipino children (9–24 months old) were analyzed. A reporter virus particle (RVP)-based neutralization assay against JEV showed neutralization in 28/29 subjects post-vaccination. Presence of DENV2-reactive antibodies was measured via DENV2 VLP ELISA, which revealed increased DENV2 binding reactivity post-vaccination. Pre-vaccination DENV2 binding reactivity also had no significant correlation with the JEV vaccine response. RVP-based neutralization and enhancement assays against DENV2 showed that there was no significant change in neutralizing or enhancing antibody activity against DENV2 after JEV vaccination. Conclusions/Significance This study shows that IMOJEV vaccination elicited a JEV neutralizing response in 97% of vaccinees and that the magnitude of JEV neutralizing titers post-vaccination was not associated with pre-existing binding antibodies to DENV2. Further, while live JEV vaccination increases DENV2-binding antibodies, this cross-reactivity does not lead to DENV2 enhancement. These findings contribute to a better understanding of the orthoflavivirus antibody response following immunization and the influence of pre-existing heterologous orthoflavivirus antibodies. This could guide vaccination strategies, especially in orthoflavivirus-endemic regions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralEncephalitis Virus, JapaneseDengue VirusJapanese Encephalitis VaccinesEncephalitis, JapaneseDengueHumansAntibodies, NeutralizingInfantChild, PreschoolPhilippinesFemaleMaleCross ReactionsSerogroupVaccinationNeutralization TestsEndemic Diseases

Substanzen

Antibodies, ViralAntibodies, NeutralizingJapanese Encephalitis Vaccines

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, College of Medicine, University of the Philippines Manila, Manila, Philippines.
  • Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island, United States of America.
  • Department of Cell and Molecular Biology, University of Rhode Island, Providence, Rhode Island, United States of America.
  • Department of Pediatrics, Cagayan Valley Medical Center, Tuguegarao City, Cagayan, Philippines.
  • Department of Pharmacology, College of Medicine, University of the Philippines Manila, Manila, Philippines.
  • Institute of Herbal Medicine, National Institutes of Health, University of the Philippines Manila, Manila, Philippines.

ORCID-Profile: Fatima Ericka S Vista

Förderung

  • NIAID NIH HHS
  • Fulbright fellowship

Zitieren

APA

Vista, F. E. S., Dalmacio, L. M. M., Solis, P. R., Maramba-Lazarte, C. N. C., Lang, D. M., Rothman, A. L., & de Paz-Silava, S. L. M. (2025). Antibody responses to Japanese encephalitis virus and dengue virus serotype 2 in children from an orthoflavivirus endemic region after IMOJEV vaccination. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0013550

Vancouver

Vista FES, Dalmacio LMM, Solis PR, Maramba-Lazarte CNC, Lang DM, Rothman AL, et al. Antibody responses to Japanese encephalitis virus and dengue virus serotype 2 in children from an orthoflavivirus endemic region after IMOJEV vaccination. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0013550

BibTeX
@article{Vista2025,
  author = {Vista, Fatima Ericka S and Dalmacio, Leslie Michelle M and Solis, Pauline R and Maramba-Lazarte, Cecilia Nelia C and Lang, Diane M and Rothman, Alan L and de Paz-Silava, Sheriah Laine M},
  title = {Antibody responses to Japanese encephalitis virus and dengue virus serotype 2 in children from an orthoflavivirus endemic region after IMOJEV vaccination},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2025},
  doi = {10.1371/journal.pntd.0013550}
}
Kostenlos starten →